Literature DB >> 2411762

Cytoplasmic immunoglobulin content in multiple myeloma.

B Barlogie, R Alexanian, M Pershouse, L Smallwood, L Smith.   

Abstract

Bone marrow cells of 82 patients with multiple myeloma were subjected to flow cytometric analysis of DNA and cytoplasmic immunoglobulin (CIg) content using propidium iodide and direct immunofluorescence assays. Except for two patients with nonsecretory myeloma, there was conformity in the immunoglobulin type derived from immunoelectrophoresis and plasma cell CIg staining. One patient with nonsecretory myeloma exhibited monotypic CIg staining, while the second showed no reaction. In eight patients with IgG lambda myeloma, the same tumor cells contained both lambda and kappa light chains, suggesting the productive rearrangement of both light chain genes. 14 patients with previously unrecognized plasma cells of low RNA content, all of whom were resistant to chemotherapy, were identified by CIg staining. By revealing previously unrecognized plasma cells with low RNA content, CIg analysis identified more patients with treatment-refractory myeloma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2411762      PMCID: PMC423897          DOI: 10.1172/JCI112033

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  16 in total

1.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

2.  Double light-chain production by leukemic cells of common clonal origin: a case report with review of pertinent literature.

Authors:  Y J Choi; M S Wong
Journal:  Am J Hematol       Date:  1981       Impact factor: 10.047

3.  Comparative studies on monotypic IgM lambda and IgG kappa from an individual patient. IV. Immunofluorescent evidence for a common clonal synthesis.

Authors:  J E Hopper
Journal:  Blood       Date:  1977-08       Impact factor: 22.113

4.  Methods and applications of flow systems for analysis and sorting of mammalian cells.

Authors:  H A Crissman; P F Mullaney; J A Steinkamp
Journal:  Methods Cell Biol       Date:  1975       Impact factor: 1.441

5.  Multiple myeloma: circulating lymphocytes that express plasma cell antigens.

Authors:  G J Ruiz-Argüelles; J A Katzmann; P R Greipp; N J Gonchoroff; J P Garton; R A Kyle
Journal:  Blood       Date:  1984-08       Impact factor: 22.113

6.  Characterization of hematologic malignancies by flow cytometry.

Authors:  B Barlogie; J Latreille; E J Freireich; C T Fu; D Mellard; M Meistrich; M Andreeff
Journal:  Blood Cells       Date:  1980

7.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.

Authors:  J H Goldie; A J Coldman
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

8.  Human immunoglobulin kappa light-chain genes are deleted or rearranged in lambda-producing B cells.

Authors:  P A Hieter; S J Korsmeyer; T A Waldmann; P Leder
Journal:  Nature       Date:  1981-04-02       Impact factor: 49.962

9.  Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre-B-cells.

Authors:  S J Korsmeyer; P A Hieter; J V Ravetch; D G Poplack; T A Waldmann; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1981-11       Impact factor: 11.205

10.  Intracytoplasmic immunofluorescence in multiple myeloma.

Authors:  G Zeile
Journal:  Cytometry       Date:  1980-07
View more
  15 in total

1.  Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells.

Authors:  R Leo; M Boeker; D Peest; R Hein; R Bartl; J E Gessner; J Selbach; G Wacker; H Deicher
Journal:  Ann Hematol       Date:  1992-03       Impact factor: 3.673

2.  Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.

Authors:  Frits van Rhee; Jackie Szymonifka; Elias Anaissie; Bijay Nair; Sarah Waheed; Yazan Alsayed; Nathan Petty; John D Shaughnessy; Antje Hoering; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2010-05-25       Impact factor: 22.113

3.  Diffuse pulmonary parenchymal involvement in multiple myeloma: antemortem diagnosis.

Authors:  Rammurti Kamble; Thomas Rosenzweig
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

4.  Suppression of abnormal karyotype predicts superior survival in multiple myeloma.

Authors:  V Arzoumanian; A Hoering; J Sawyer; F van Rhee; C Bailey; J Gurley; J D Shaughnessy; E Anaissie; J Crowley; B Barlogie
Journal:  Leukemia       Date:  2008-01-17       Impact factor: 11.528

5.  Expression of the neural cell adhesion molecule (CD56) by human myeloma cells.

Authors:  J Drach; C Gattringer; H Huber
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

6.  Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells.

Authors:  Tae-Dong Jeong; Chan-Jeoung Park; Hyoeun Shim; Seongsoo Jang; Hyun-Sook Chi; Dok Hyun Yoon; Dae-Young Kim; Jung-Hee Lee; Je-Hwan Lee; Cheolwon Suh; Kyoo Hyung Lee
Journal:  Korean J Hematol       Date:  2012-12-24

7.  F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.

Authors:  Twyla B Bartel; Jeff Haessler; Tracy L Y Brown; John D Shaughnessy; Frits van Rhee; Elias Anaissie; Terri Alpe; Edgardo Angtuaco; Ronald Walker; Joshua Epstein; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

8.  Biphenotypic plasma cell myeloma: two cases of plasma cell neoplasm with a coexpression of kappa and lambda light chains.

Authors:  Shahanawaz Jiwani; Joshua Bornhost; Daisy Alapat
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

9.  VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.

Authors:  M Pineda-Roman; M Zangari; F van Rhee; E Anaissie; J Szymonifka; A Hoering; N Petty; J Crowley; J Shaughnessy; J Epstein; B Barlogie
Journal:  Leukemia       Date:  2008-04-24       Impact factor: 11.528

10.  High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.

Authors:  Frits van Rhee; Vanessa Bolejack; Klaus Hollmig; Mauricio Pineda-Roman; Elias Anaissie; Joshua Epstein; John D Shaughnessy; Maurizio Zangari; Guido Tricot; Abid Mohiuddin; Yazan Alsayed; Gail Woods; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2007-04-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.